Your browser doesn't support javascript.
loading
Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection.
Thaweethai, Tanayott; Jolley, Sarah E; Karlson, Elizabeth W; Levitan, Emily B; Levy, Bruce; McComsey, Grace A; McCorkell, Lisa; Nadkarni, Girish N; Parthasarathy, Sairam; Singh, Upinder; Walker, Tiffany A; Selvaggi, Caitlin A; Shinnick, Daniel J; Schulte, Carolin C M; Atchley-Challenner, Rachel; Alba, George A; Alicic, Radica; Altman, Natasha; Anglin, Khamal; Argueta, Urania; Ashktorab, Hassan; Baslet, Gaston; Bassett, Ingrid V; Bateman, Lucinda; Bedi, Brahmchetna; Bhattacharyya, Shamik; Bind, Marie-Abele; Blomkalns, Andra L; Bonilla, Hector; Bush, Patricia A; Castro, Mario; Chan, James; Charney, Alexander W; Chen, Peter; Chibnik, Lori B; Chu, Helen Y; Clifton, Rebecca G; Costantine, Maged M; Cribbs, Sushma K; Davila Nieves, Sylvia I; Deeks, Steven G; Duven, Alexandria; Emery, Ivette F; Erdmann, Nathan; Erlandson, Kristine M; Ernst, Kacey C; Farah-Abraham, Rachael; Farner, Cheryl E; Feuerriegel, Elen M; Fleurimont, Judes.
Afiliação
  • Thaweethai T; Massachusetts General Hospital, Boston.
  • Jolley SE; Harvard Medical School, Boston, Massachusetts.
  • Karlson EW; University of Colorado Anschutz Medical Campus, Aurora.
  • Levitan EB; Brigham and Women's Hospital, Boston, Massachusetts.
  • Levy B; University of Alabama at Birmingham.
  • McComsey GA; Harvard Medical School, Boston, Massachusetts.
  • McCorkell L; Brigham and Women's Hospital, Boston, Massachusetts.
  • Nadkarni GN; Case Western Reserve University, Cleveland, Ohio.
  • Parthasarathy S; Patient-Led Research Collaborative, Calabasas, California.
  • Singh U; Icahn School of Medicine at Mount Sinai, New York, New York.
  • Walker TA; The University of Arizona College of Medicine, Tucson.
  • Selvaggi CA; Stanford University School of Medicine, Stanford, California.
  • Shinnick DJ; Emory University School of Medicine, Atlanta, Georgia.
  • Schulte CCM; Massachusetts General Hospital, Boston.
  • Atchley-Challenner R; Massachusetts General Hospital, Boston.
  • Alba GA; Massachusetts General Hospital, Boston.
  • Alicic R; Mass General Brigham, Boston, Massachusetts.
  • Altman N; Massachusetts General Hospital, Boston.
  • Anglin K; University of Washington, Seattle.
  • Argueta U; University of Colorado Anschutz Medical Campus, Aurora.
  • Ashktorab H; University of California, San Francisco.
  • Baslet G; University of California, San Francisco.
  • Bassett IV; Howard University, Washington, DC.
  • Bateman L; Brigham and Women's Hospital, Boston, Massachusetts.
  • Bedi B; Massachusetts General Hospital, Boston.
  • Bhattacharyya S; Bateman Horne Center, Salt Lake City, Utah.
  • Bind MA; Emory University School of Medicine, Atlanta, Georgia.
  • Blomkalns AL; Brigham and Women's Hospital, Boston, Massachusetts.
  • Bonilla H; Massachusetts General Hospital, Boston.
  • Bush PA; Stanford University, Stanford, California.
  • Castro M; Stanford University, Stanford, California.
  • Chan J; Kaiser Foundation Health Plan of Georgia Inc, Atlanta.
  • Charney AW; University of Kansas Medical Center, Kansas City.
  • Chen P; Massachusetts General Hospital, Boston.
  • Chibnik LB; Icahn School of Medicine at Mount Sinai, New York, New York.
  • Chu HY; Cedars-Sinai Medical Center, Los Angeles, California.
  • Clifton RG; Massachusetts General Hospital, Boston.
  • Costantine MM; University of Washington School of Medicine, Seattle.
  • Cribbs SK; George Washington University, Washington, DC.
  • Davila Nieves SI; The Ohio State University, Columbus.
  • Deeks SG; Emory University School of Medicine, Atlanta, Georgia.
  • Duven A; Universidad de Puerto Rico Recinto de Ciencias Medicas, San Juan, Puerto Rico.
  • Emery IF; University of California, San Francisco.
  • Erdmann N; Swedish Medical Center, Seattle, Washington.
  • Erlandson KM; MaineHealth, Portland.
  • Ernst KC; University of Alabama at Birmingham.
  • Farah-Abraham R; University of Colorado Anschutz Medical Campus, Aurora.
  • Farner CE; The University of Arizona, Tucson.
  • Feuerriegel EM; Emory University, Atlanta, Georgia.
  • Fleurimont J; The University of Texas Health Science Center at San Antonio.
JAMA ; 329(22): 1934-1946, 2023 06 13.
Article em En | MEDLINE | ID: mdl-37278994
ABSTRACT
Importance SARS-CoV-2 infection is associated with persistent, relapsing, or new symptoms or other health effects occurring after acute infection, termed postacute sequelae of SARS-CoV-2 infection (PASC), also known as long COVID. Characterizing PASC requires analysis of prospectively and uniformly collected data from diverse uninfected and infected individuals.

Objective:

To develop a definition of PASC using self-reported symptoms and describe PASC frequencies across cohorts, vaccination status, and number of infections. Design, Setting, and

Participants:

Prospective observational cohort study of adults with and without SARS-CoV-2 infection at 85 enrolling sites (hospitals, health centers, community organizations) located in 33 states plus Washington, DC, and Puerto Rico. Participants who were enrolled in the RECOVER adult cohort before April 10, 2023, completed a symptom survey 6 months or more after acute symptom onset or test date. Selection included population-based, volunteer, and convenience sampling. Exposure SARS-CoV-2 infection. Main Outcomes and

Measures:

PASC and 44 participant-reported symptoms (with severity thresholds).

Results:

A total of 9764 participants (89% SARS-CoV-2 infected; 71% female; 16% Hispanic/Latino; 15% non-Hispanic Black; median age, 47 years [IQR, 35-60]) met selection criteria. Adjusted odds ratios were 1.5 or greater (infected vs uninfected participants) for 37 symptoms. Symptoms contributing to PASC score included postexertional malaise, fatigue, brain fog, dizziness, gastrointestinal symptoms, palpitations, changes in sexual desire or capacity, loss of or change in smell or taste, thirst, chronic cough, chest pain, and abnormal movements. Among 2231 participants first infected on or after December 1, 2021, and enrolled within 30 days of infection, 224 (10% [95% CI, 8.8%-11%]) were PASC positive at 6 months. Conclusions and Relevance A definition of PASC was developed based on symptoms in a prospective cohort study. As a first step to providing a framework for other investigations, iterative refinement that further incorporates other clinical features is needed to support actionable definitions of PASC.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: JAMA Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: JAMA Ano de publicação: 2023 Tipo de documento: Article
...